&l;p&g;&l;img class=&q;dam-image bloomberg size-large wp-image-34161695&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/34161695/960×0.jpg?fit=scale&q; data-height=&q;625&q; data-width=&q;960&q;&g; Nursing home, assisted living and other long-term care costs are rising as financial concerns for retirees, according to a new poll. Photo&a;nbsp;credit: Emile Wamsteker/Bloomberg News.
Long-term care and overall medical expenses are growing as financial worries for retirees. Nearly half of&a;nbsp;seniors have little or no confidence they have enough money for nursing homes and other long-care.
That worry grew to 49% this year, up from 45%&a;nbsp;last year, in the annual retirement confidence survey released today by the Employee Benefit Research Institute (EBRI), a non-partisan Washington think tank.
Twice as many retirees requiring long-term care in the last five years said the expense was much higher than expected compared to&a;nbsp;the elderly who haven&a;rsquo;t needed the intense medical assistance (22% versus 11%).
Top 5 Medical Stocks To Buy For 2019: Cannabis Science, Inc. (CBIS)
- [By Peter Graham]
A long term performance chart shows GW Pharmaceuticals PLC outperforming other small cap marijuana stocks like Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), Cannabis Science Inc (OTCMKTS: CBIS) and Medical Marijuana Inc (OTCMKTS: MJNA), but that outperformance has come withconsiderable volatility:
- [By Matthew Briar]
Look out Cannabis Science Inc (OTCMKTS:CBIS), and step aside Medical Marijuana Inc (OTCMKTS:MJNA). There’s a new cannabis name on the scene…. Algae Dynamics Corp. (OTCMKTS:ADYNF). It may not be known (or named) like its marijuana peers, but give it time. This small cap company has a very big idea, and it’s going to sprout soon.
Yes, Algae Dynamics is an algae company. It’s not just an algae company though.
Algae Dynamics is the owner of the proprietary BioSilo ™ process. BioSilo is a way of growing algae quickly and effectively…. a mix of an open-pond system and a photobioreactor, which is a light-driven approach to growing algae. It can be viewed as a “best of both worlds” approach, lowering the typical cost of algae farming, while the modular design makes it easy to maintain.
The company could go a lot of directions with the technology, Most of the tens of thousands of species of algae are rather flexible in how they can be purposed, and what they can become. Algae Dynamics is first focused on the development of two kinds of products though…. Chlorella, and Omega-3.
Chlorella is a type of microalgae that can be processed into a consumable powder by drying it until it takes a powder form, similar to coffee. Chlorella is rich in minerals, prebiotics, vitamins, and other nutritional substances. It can be added to a baked goods and a number of other products, or taken as a supplement on its own. Chlorella is used in over 1,000 products in the food and beverage markets. Algae Dynamics estimates the global Chlorella market was $210.3 million in 2014 and is expected to reach $265.5 million in 2018.
Despite a market for Chlorella in North America, there are no commercial North American producers of it.
Due to its health benefits, Omega-3 oil can be added to a very wide range of products. Consumers are increasingly aware of these benefits too, leading to substantial growth in the industry; health supplements compr
- [By Peter Graham]
A long term performance chart shows GW Pharmaceuticals PLC outperforming other marijuana stocks like Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), Cannabis Science Inc (OTCMKTS: CBIS) and Medical Marijuana Inc (OTCMKTS: MJNA), but shares are also once again falling off from all-time highs:
- [By Jim Robertson]
When investors think of cannabinoid or marijuana stocks, they either think of better known stocks likeGW Pharmaceuticals PLC (NASDAQ: GWPH)and Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) that trade on bigger exchanges orCannabis Science Inc (OTCMKTS: CBIS) and Medical Marijuana Inc (OTCMKTS: MJNA) that are stilllisted on the OTC. However, there are other more indirect ways to invest in growing cannabinoid or marijuana acceptance.
Top 5 Medical Stocks To Buy For 2019: Flowserve Corporation(FLS)
- [By Damon Churchwell]
Increasing sales and margins
A second, even larger, flow technology company to consider is Flowserve (NYSE: FLS ) . The company’s flow control systems are utilized by a wide range of industries, led by oil & gas, chemicals, and power generation.
Top 5 Medical Stocks To Buy For 2019: Identiv, Inc.(INVE)
- [By Lisa Levin]
The industries that are driving the market today are:
Cement: This industry gained 3.4 percent by 2:30 pm. The top stock within the industry was Cemex SAB de CV (ADR) (NYSE: CX), which gained 4.7 percent. Cemex’s PEG ratio is 0.16.
Computer Peripherals: This industry rose 2.6 percent by 2:30 pm ET. The top performer in this industry was Identiv Inc (NASDAQ: INVE), which gained 13.5 percent. Identiv shares have climbed 44.83 percent over the past 52 weeks, while the S&P 500 index has increased 8.61 percent in the same period.
Internet Service Providers: The industry gained 2 percent by 2:30 pm. The top performer in this industry was TrueCar Inc (NASDAQ: TRUE) which gained 3.4 percent. TrueCar shares have jumped 60.90 percent over the past 52 weeks, while the S&P 500 index has increased 8.61 percent in the same period.
Regional – Southwest Banks: This industry moved up 1.9 percent by 2:30 pm. The top performer in this industry was Veritex Holdings Inc (NASDAQ: VBTX), which rose 6.6 percent
Top 5 Medical Stocks To Buy For 2019: Sanofi(SNY)
- [By Ben Levisohn]
Hopes were high for MannKind (MNKD) when its inhaled insulin Afrezza was approved by the FDA more than two years ago. At the time, Barron’s warned that it was time to dump MannKind’s shares, something that now seems prescient, as its shares have since tumbled 95%. No wonder, as the news since then has been far from good. MannKind found a partner in Sanofi (SNY), only to get dumped in early 2016, and has since been forced to sell property to raise cash. And now MannKind could be on the verge of being delisted from the Nasdaq due to its sub $1 stock price. What now? Piper Jaffray’sJoshua Schimmer and team see a reverse stock split in MannKind’s future:
- [By ]
While vaccines are not thought to be as effective this year, the severity of the season could drive higher volume for drug makers. Experts have said the AstraZeneca (NYSE: AZN) vaccine FluMist may not be effective against this year’s strain of flu and are instead recommending the Sanofi (NYSE: SNY) FluZone vaccine. GlaxoSmithKline (NYSE: GSK) has recently been approved for use of its FluLaval vaccine in children as young as six months.
- [By Money Morning News Team]
And the first pharmaceutical stock on our list is expecting an 8.2 % increase in revenue over the next three years from the sale of its newest drug…
Pharmaceutical Stocks to Buy, No. 3: Sanofi SA(NYSE: SNY)
Sanofi SA (NYSE:SNY) is expecting revenue growth of over 8% thanks to its new drug, Dupixent. The drug was made available by prescription in March to treat extreme cases of eczema. It is the first injection to treat the skin condition.
- [By Todd Campbell]
Biogen’s suite of MS drugs makes it the biggest maker of multiple sclerosis drugs, by market share, but Teva Pharmaceutical, Novartis (NYSE:NVS), and Sanofi SA (NYSE:SNY) are also racking up billions in sales annually in the indication.
Top 5 Medical Stocks To Buy For 2019: CyberArk Software Ltd.(CYBR)
- [By Joe Tenebruso]
CyberArk Software (NASDAQ:CYBR) reported fourth-quarter financial results on Feb. 9. The Israeli cybersecurity specialist continues to win new business for its “privileged account” security solutions, which help to protect against cyberattacks that use insider privileges to penetrate network perimeters and assault the most sensitive areas of an enterprise’s IT infrastructure.
- [By ]
RB: I thought wed be up more than we are on cybersecurity plays. We have 25% gains on recommendations like Palo Alto Networks (NYSE: PANW). Were off a few percentage points on CyberArk Software (NASDAQ: CYBR).
- [By Lisa Levin]
Some of the stocks that may grab investor focus today are:
Wall Street expects Citigroup Inc (NYSE: C) to report quarterly earnings at $1.26 per share on revenue of $17.71 billion before the opening bell. Citigroup shares rose 0.30 percent to $67.22 in after-hours trading.
Analysts are expecting JPMorgan Chase & Co. (NYSE: JPM) to have earned $1.65 per share on revenue of $25.61 billion in the latest quarter. JPMorgan will release earnings before the markets open. JPMorgan shares gained 0.48 percent to $93.55 in after-hours trading.
Cyberark Software Ltd (NASDAQ: CYBR) lowered its guidance for the second quarter. The company now expects total revenue of $57.0 million to $57.5 million, versus earlier guidance of $61.0 million to $62.0 million. Cyberark shares dipped 17.65 percent to $42.00 in the after-hours trading session.
Before the opening bell, First Republic Bank (NYSE: FRC) is projected to report quarterly earnings at $1.1 per share on revenue of $675.70 million. First Republic Bank shares dropped 0.80 percent to close at $101.35 on Thursday.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
- [By Chris Lange]
The short interest at CyberArk Software Ltd. (NASDAQ: CYBR) increased to 1.10 million shares from the previous level of 861,800. Shares were trading at $53.34, within a 52-week range of $39.34 to $55.63.